NASDAQ:GNFT Genfit - GNFT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. $4.36 +0.18 (+4.31%) (As of 01/27/2023 04:02 PM ET) Add Compare Share Share Today's Range$4.16▼$4.3650-Day Range$3.53▼$4.3952-Week Range$3.02▼$5.05Volume4,964 shsAverage Volume10,265 shsMarket Capitalization$217.28 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Genfit MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside129.4% Upside$10.00 Price TargetShort InterestBearish0.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.81) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.74 out of 5 starsMedical Sector880th out of 1,055 stocksBiological Products, Except Diagnostic Industry142nd out of 170 stocks 3.5 Analyst's Opinion Consensus RatingGenfit has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Genfit has a forecasted upside of 129.4% from its current price of $4.36.Amount of Analyst CoverageGenfit has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.25% of the float of Genfit has been sold short.Short Interest Ratio / Days to CoverGenfit has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Genfit has recently increased by 4.04%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGenfit does not currently pay a dividend.Dividend GrowthGenfit does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GNFT. Previous Next 1.9 News and Social Media Coverage News SentimentGenfit has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Genfit this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genfit insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of Genfit is held by insiders.Percentage Held by InstitutionsOnly 4.54% of the stock of Genfit is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Genfit are expected to grow in the coming year, from ($0.81) to ($0.07) per share.Price to Book Value per Share RatioGenfit has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Genfit (NASDAQ:GNFT) StockGenfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.Read More Receive GNFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter. Email Address GNFT Stock News HeadlinesJanuary 5, 2023 | finance.yahoo.comGENFIT to Participate in Upcoming Investor ConferencesOctober 10, 2022 | benzinga.com12 Health Care Stocks Moving In Monday's Pre-Market Session - Acer Therapeutics (NASDAQ:ACER), Avadel Pha - BenzingaJanuary 27, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…September 30, 2022 | globenewswire.comGENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis - GlobeNewswireSeptember 28, 2022 | globenewswire.comGENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update - GlobeNewswireSeptember 19, 2022 | finance.yahoo.comGenfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases - Yahoo FinanceSeptember 19, 2022 | finance.yahoo.comGenfit To Buy This Swiss Firm Expanding Its Portfolio in Liver DiseasesSeptember 19, 2022 | uk.finance.yahoo.comNicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trial - Yahoo Finance UKJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.September 19, 2022 | seekingalpha.comGenfit to acquire Swiss-based Versantis in liver diseases biotech (NASDAQ:GNFT) - Seeking AlphaSeptember 19, 2022 | globenewswire.comGENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases - GlobeNewswireSeptember 13, 2022 | benzinga.comGenfit (NASDAQ:GNFT) – GENFIT Announces FDA Has Granted Orphan Drug Designation To GNS5611, For The Treat - BenzingaSeptember 13, 2022 | globenewswire.comFDA Grants GENFIT's GNS561 Orphan Drug Designation for the - GlobeNewswireSeptember 12, 2022 | streetinsider.comGenSight Biologics Strengthens Its Management Team to Support the Launch of LUMEVOQ® in Europe - StreetInsider.comSeptember 7, 2022 | seekingalpha.comGenfit S.A.: A 'Sum Of The Parts' Story (NASDAQ:GNFT) - Seeking AlphaSeptember 4, 2022 | reuters.comGNFT.PA - Genfit SA | Stock Price & Latest News | ReutersAugust 19, 2022 | benzinga.comAnalyzing Genfit's Short Interest - BenzingaAugust 18, 2022 | streetinsider.comSELLAS Life Sciences (SLS) Appoints Katherine Bach Kalin to its Board - StreetInsider.comAugust 16, 2022 | finance.yahoo.comSELLAS Life Sciences’ Announces Election of Katherine Bach Kalin to its Board of Directors - Yahoo FinanceJuly 29, 2022 | businesswire.comNon-alcoholic Steatohepatitis Biomarkers Market Analysis: Hepatic Fibrosis, Serum, Oxidative Stress, Apoptosis - Global Forecast to 2029 - ResearchAndMarkets.com - Business WireJuly 8, 2022 | barrons.comIntercept Will Ask Yet Again for FDA to Approve Its NASH Drug - Barron'sJuly 8, 2022 | rttnews.comPre-market Movers: DBD, SRG, ISIG, UPST, CSSE… - RTTNewsJune 22, 2022 | globenewswire.comNonalcoholic Steatohepatitis Therapeutics Market Expands with Rising Cases of Obesity and Diabetes, States TMR Report - GlobeNewswireJune 14, 2022 | seekingalpha.comGelesis, Entrada top healthcare gainers; Outset Medical, Arcellx lead losers' pack - Seeking AlphaJune 8, 2022 | nasdaq.comPre-market Movers: XCUR, CYRN, EFOI, NVAX, AERC… - NasdaqMay 25, 2022 | finance.yahoo.comGENFIT: May 25, 2022 Combined Shareholders Meeting results - Yahoo FinanceMay 12, 2022 | finance.yahoo.comGENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS) - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GNFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter. Email Address GNFT Company Calendar Today1/27/2023Next Earnings (Estimated)4/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNFT CUSIPN/A CIK1757064 Webwww.genfit.com Phone(332) 016-4000FaxN/AEmployees122Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+129.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.66 Current Ratio6.33 Quick Ratio6.33 Sales & Book Value Annual Sales$101.25 million Price / Sales2.15 Cash Flow$1.68 per share Price / Cash Flow2.60 Book Value$2.83 per share Price / Book1.54Miscellaneous Outstanding Shares49,835,000Free Float47,742,000Market Cap$217.28 million OptionableNot Optionable Beta1.28 Key ExecutivesPascal PrigentChief Executive OfficerPascal CaiseyChief Operating OfficerThomas BaetzChief Financial OfficerDean W. HumChief Scientific OfficerCarol L. AddyChief Medical OfficerKey CompetitorsProKidneyNASDAQ:PROKSOPHiA GENETICSNASDAQ:SOPHARYA Sciences Acquisition Corp IVNASDAQ:ARYDJATT AcquisitionNYSE:JATTAcumen PharmaceuticalsNASDAQ:ABOSView All CompetitorsInsiders & InstitutionsBNP Paribas Arbitrage SNCBought 11,279 shares on 11/16/2022Ownership: 0.024%Tang Capital Management LLCSold 63,920 shares on 11/15/2022Ownership: 2.404%Two Sigma Investments LPSold 15,640 shares on 11/15/2022Ownership: 0.130%Citadel Advisors LLCBought 22,786 shares on 11/15/2022Ownership: 0.071%Optiver Holding B.V.Sold 20,524 shares on 11/14/2022Ownership: 0.036%View All Institutional Transactions GNFT Stock - Frequently Asked Questions Should I buy or sell Genfit stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genfit in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GNFT shares. View GNFT analyst ratings or view top-rated stocks. What is Genfit's stock price forecast for 2023? 1 Wall Street analysts have issued 12 month target prices for Genfit's shares. Their GNFT share price forecasts range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 139.2% from the stock's current price. View analysts price targets for GNFT or view top-rated stocks among Wall Street analysts. How have GNFT shares performed in 2023? Genfit's stock was trading at $4.3890 at the start of the year. Since then, GNFT shares have decreased by 4.8% and is now trading at $4.18. View the best growth stocks for 2023 here. When is Genfit's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 6th 2023. View our GNFT earnings forecast. What is Jean-François Mouney's approval rating as Genfit's CEO? 3 employees have rated Genfit Chief Executive Officer Jean-François Mouney on Glassdoor.com. Jean-François Mouney has an approval rating of 29% among the company's employees. This puts Jean-François Mouney in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Genfit own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), STAG Industrial (STAG), Gilead Sciences (GILD), Occidental Petroleum (OXY), Vaxart (VXRT), Exxon Mobil (XOM), Zynerba Pharmaceuticals (ZYNE), Aimmune Therapeutics (AIMT) and Amarin (AMRN). When did Genfit IPO? (GNFT) raised $132 million in an initial public offering on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays served as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers. What is Genfit's stock symbol? Genfit trades on the NASDAQ under the ticker symbol "GNFT." How do I buy shares of Genfit? Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Genfit's stock price today? One share of GNFT stock can currently be purchased for approximately $4.18. How much money does Genfit make? Genfit (NASDAQ:GNFT) has a market capitalization of $208.31 million and generates $101.25 million in revenue each year. How many employees does Genfit have? The company employs 122 workers across the globe. How can I contact Genfit? Genfit's mailing address is PARC 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The official website for the company is www.genfit.com. The company can be reached via phone at (332) 016-4000 or via email at investors@genfit.com. This page (NASDAQ:GNFT) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.